No Data
Solid Earnings May Not Tell The Whole Story For Lushang Freda PharmaceuticalLtd (SHSE:600223)
Freda: Report of Lushang Freda Pharmaceutical Co., Ltd. for the third quarter of 2024
Announcement of Lushang Freda Pharmaceutical Co., Ltd. on the main operating data for the third quarter of 2024
Lushang Freda Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024
Lushang Freda Pharmaceutical (600223.SH) released its performance for the first three quarters, with a net income of 0.171 billion yuan, a year-on-year decrease of 28.09%.
Lushang Freda (600223.SH) released the third quarter report of 2024, with the company's revenue for the first three quarters reaching 28....
Lushang Freda Pharmaceutical (600223.SH): The net income in the first three quarters was 0.171 billion yuan, a 28.09% year-on-year decrease.
On October 28th, Ge Longhui reported that Lushang Freda (600223.SH) announced that in the first three quarters of 2024, the total operating income was 2.803 billion yuan, a year-on-year decrease of 17.45%; the net income attributable to the parent company's shareholders was 0.171 billion yuan, a year-on-year decrease of 28.09%; and the basic earnings per share was 0.17 yuan.
Despite the Downward Trend in Earnings at Lushang Freda PharmaceuticalLtd (SHSE:600223) the Stock Climbs 5.4%, Bringing Five-year Gains to 157%No Data
No Data
